Ebixa for Moderate-to-severe Alzheimer's disease
Quick answer: Ebixa is used for Moderate-to-severe Alzheimer's disease as part of a nmda receptor antagonist treatment regimen. Memantine is a low-affinity, voltage-dependent NMDA receptor antagonist that reduces glutamate-mediated excitotoxicity The specific dosing for Moderate-to-severe Alzheimer's disease is determined by your prescriber based on individual factors.
Why is Ebixa used for Moderate-to-severe Alzheimer's disease?
Ebixa belongs to the NMDA receptor antagonist class. Memantine is a low-affinity, voltage-dependent NMDA receptor antagonist that reduces glutamate-mediated excitotoxicity This action makes it useful for treating or managing Moderate-to-severe Alzheimer's disease in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Ebixa is the right choice for a specific patient depends on the type and severity of Moderate-to-severe Alzheimer's disease, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Moderate-to-severe Alzheimer's disease
Common adult dosing range: 5-20 mg daily (titrated weekly). The actual dose for Moderate-to-severe Alzheimer's disease depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Ebixa medicine page.
What to expect
Ebixa treatment for Moderate-to-severe Alzheimer's disease typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Moderate-to-severe Alzheimer's disease
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Ebixa is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all NMDA receptor antagonist for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Ebixa
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Ebixa full prescribing information · All NMDA receptor antagonist alternatives
Frequently asked questions
How effective is Ebixa for Moderate-to-severe Alzheimer's disease?
Effectiveness varies by individual response, dose, and severity. Ebixa is one of several treatment options for Moderate-to-severe Alzheimer's disease, supported by clinical evidence within the nmda receptor antagonist class. Discuss expected response with your prescriber.
How long do I need to take Ebixa for Moderate-to-severe Alzheimer's disease?
Treatment duration depends on the nature of Moderate-to-severe Alzheimer's disease — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Ebixa when used for Moderate-to-severe Alzheimer's disease?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Ebixa for Moderate-to-severe Alzheimer's disease?
Yes. Multiple medicines and non-drug options exist for Moderate-to-severe Alzheimer's disease. Alternatives within the nmda receptor antagonist class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.